KROS Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of -13648.45% compared to Keros Therapeutics's net margin of 25.86%. Keros Therapeutics's return on equity of -44.6% beat Corcept Therapeutics's return on equity of 25.77%.

Keros Therapeutics has a consensus price target of $43.55, signalling upside risk potential of 239.67%. On the other hand Corcept Therapeutics has an analysts' consensus of -- which suggests that it could grow by 46.69%. Given that Keros Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Keros Therapeutics is more attractive than Corcept Therapeutics.

Keros Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.46%.

Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Keros Therapeutics quarterly revenues are $388K, which are smaller than Corcept Therapeutics quarterly revenues of $182.5M. Keros Therapeutics's net income of -$53M is lower than Corcept Therapeutics's net income of $47.2M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 40.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 686.85x versus 9.05x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -13648.45% compared to Keros Therapeutics's net margin of 36.03%. Keros Therapeutics's return on equity of -44.6% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Keros Therapeutics has a consensus price target of $43.55, signalling upside risk potential of 239.67%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,029.20 which suggests that it could grow by 44.61%. Given that Keros Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Keros Therapeutics is more attractive than Regeneron Pharmaceuticals.

Keros Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Keros Therapeutics quarterly revenues are $388K, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Keros Therapeutics's net income of -$53M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 686.85x versus 5.96x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding has a net margin of -13648.45% compared to Keros Therapeutics's net margin of --. Keros Therapeutics's return on equity of -44.6% beat Scholar Rock Holding's return on equity of --.

Keros Therapeutics has a consensus price target of $43.55, signalling upside risk potential of 239.67%. On the other hand Scholar Rock Holding has an analysts' consensus of $46.38 which suggests that it could grow by 8.86%. Given that Keros Therapeutics has higher upside potential than Scholar Rock Holding, analysts believe Keros Therapeutics is more attractive than Scholar Rock Holding.

Keros Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Scholar Rock Holding has a beta of 0.524, suggesting its less volatile than the S&P 500 by 47.627%.

Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Scholar Rock Holding pays out -- of its earnings as a dividend.

Keros Therapeutics quarterly revenues are $388K, which are larger than Scholar Rock Holding quarterly revenues of --. Keros Therapeutics's net income of -$53M is higher than Scholar Rock Holding's net income of -$64.5M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Scholar Rock Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 686.85x versus 86.19x for Scholar Rock Holding. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics has a net margin of -13648.45% compared to Keros Therapeutics's net margin of --. Keros Therapeutics's return on equity of -44.6% beat Trevi Therapeutics's return on equity of --.

Keros Therapeutics has a consensus price target of $43.55, signalling upside risk potential of 239.67%. On the other hand Trevi Therapeutics has an analysts' consensus of $9.94 which suggests that it could grow by 149.23%. Given that Keros Therapeutics has higher upside potential than Trevi Therapeutics, analysts believe Keros Therapeutics is more attractive than Trevi Therapeutics.

Keros Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.433%.

Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

Keros Therapeutics quarterly revenues are $388K, which are larger than Trevi Therapeutics quarterly revenues of --. Keros Therapeutics's net income of -$53M is lower than Trevi Therapeutics's net income of -$13.2M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 686.85x versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.